Table 3 |
||||
|
Results of clinical trials by genotyping modality |
||||
|
Study Location |
Treatment Arm |
Genotyping-corrected 42-day Risk of Treatment Failure, % (95% CI) |
Risk Difference, Gel vs. CE, % (p value) |
|
|
|
||||
|
Gel |
CE |
|||
|
Kanungu |
AL |
6.9 (3.8-12.1) |
5.5 (2.9-10.3) |
1.4 (0.4) |
|
DP |
2.4 (1.0-5.7) |
2.9 (1.3-6.3) |
-0.5 (0.5) |
|
|
Risk Difference, AL vs. DP, % (p value) |
4.5 (0.07) |
2.6 (0.3) |
||
|
Apac |
AL |
17.0 (11.8-24.0) |
10.7 (6.6-17.1) |
6.3 (0.02) |
|
DP |
8.5 (5.2-13.7) |
3.4 (1.5-7.4) |
5.1 (0.03) |
|
|
Risk Difference, AL vs. DP, % (p value) |
8.5 (0.03) |
7.3 (0.02) |
||
|
|
||||
|
Risks of treatment failure calculated using the Kaplan-Meier product limit formula; p-values for risk differences calculated from 1,000 bootstrap repetitions. |
||||
|
Gupta et al. Malaria Journal 2010 9:19 doi:10.1186/1475-2875-9-19 |
||||
